 SINGAPORE, Nov. 09, 2020 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals Nasdaq:ASLN, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities. 